NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $296,000 | +2.8% | 16,483 | -1.6% | 0.01% | 0.0% |
| Q2 2021 | $288,000 | -16.3% | 16,755 | -2.5% | 0.01% | -14.3% |
| Q1 2021 | $344,000 | +19.0% | 17,192 | +1.1% | 0.01% | 0.0% |
| Q4 2020 | $289,000 | +0.3% | 17,006 | -2.1% | 0.01% | 0.0% |
| Q3 2020 | $288,000 | -30.8% | 17,373 | -3.3% | 0.01% | -36.4% |
| Q2 2020 | $416,000 | +29.2% | 17,960 | -0.6% | 0.01% | +22.2% |
| Q1 2020 | $322,000 | -17.4% | 18,060 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $390,000 | +20.0% | 18,060 | +1.2% | 0.01% | +28.6% |
| Q3 2019 | $325,000 | -48.8% | 17,839 | 0.0% | 0.01% | -53.3% |
| Q2 2019 | $635,000 | +7.4% | 17,839 | +1.4% | 0.02% | +7.1% |
| Q1 2019 | $591,000 | +3.1% | 17,587 | +0.9% | 0.01% | -6.7% |
| Q4 2018 | $573,000 | -47.1% | 17,431 | -1.9% | 0.02% | -42.3% |
| Q3 2018 | $1,083,000 | +36.1% | 17,760 | +8.9% | 0.03% | +30.0% |
| Q2 2018 | $796,000 | -54.6% | 16,311 | -1.2% | 0.02% | -55.6% |
| Q1 2018 | $1,754,000 | – | 16,511 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |